Tampa-based 1AB is handling Moderna Therapeutics, which on March 16 began the first US clinical trial for a coronavirus vaccine
The Cambridge, MA-based biotech's MRNA-1273 product is participating in the dosed Phase 1 study conducted by the National Institutes of Health under its Investigational New Drug application.
The study of 45 healthy adults is expected "to provide important information about safety and immunogenicity," according to Tal Zaks, chief medical officer at Moderna, which is preparing for a Phase 2 study based on the data collected from Phase 1.
Moderna has strategic alliances with Merck, AstraZeneca, Pentagon's Defense Advanced Research Projects Agency and Biomedical Advanced Research and Development Authority, which is part of the Dept. of Health and Human Services.
Katie Engleman, 1AB managing director handles the Moderna push. She joined the life sciences strategic communications shop in 2018 following a 10-year stint at W2O's Pure Communications unit.